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Abstract
Background: Although the tuberculin skin test (TST) is frequently used to aid in the diagnosis of tuberculosis (TB) disease
and to identify persons with latent TB infection, it is an imperfect test and approximately 10–25% of persons with
microbiologically confirmed TB disease have a negative TST. Previous studies have suggested that persons with a negative
TST are more likely to present with severe TB disease and have an increased rate of TB-related death.
Methods: We analyzed culture-confirmed TB cases captured in US TB surveillance data from 1993 to 2008 and performed
multivariate logistic regression analysis to determine the association between TST result and death.
Results: Of 284,866 cases of TB reported in the US, 58,180 persons were eligible for inclusion in the analysis and 3,270 of
those persons died after initiating TB treatment. Persons with a negative TST accounted for only 14% of the eligible cases
but accounted for 42% of the deaths. Persons with a TST$15 mm had 67% lower odds of death than persons with a
negative TST (adjusted odds ratio 0.33, 95% confidence interval 0.30–0.36).
Conclusions: A negative TST is associated with an increased risk of death among persons with culture-confirmed TB disease,
even after adjustment for HIV status, site of TB disease, sputum smear AFB status, drug susceptibility, age, sex, and origin of
birth. In addition to indicating risk of developing disease, the TST may also be a marker for increased risk of death.
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Introduction
Since its introduction in 1890 the tuberculin skin test (TST) has
been widely adopted to test for infection with Mycobacterium tuberculosis
complex (MTBC), both to aid in the diagnosis of tuberculosis disease
and to identify individuals with latent tuberculosis infection who
might benefit from treatment to prevent progression to TB disease.
[1,2] A positive TST result is based on measurable skin induration in
response to intradermally injected purified protein derivative
antigens and relies on memory cell immune responses to mycobac-
terial antigens. However, approximately 10–25% of patients with
microbiologically confirmed, active TB disease do not respond to
tuberculin and have a negative TST result. [1,3,4] Thus, in these
individuals the negative TST result does not correspond to
microbiologically confirmed M. tuberculosis infection.
Previous studies have shown that adults with active TB and a
negative TST are more likely to have disseminated disease or
pulmonary disease with severe illness. [1,5,6] Similarly, young
children, people with HIV infection, and people with other
immunocompromising conditions such as malnutrition with active
TB are more likely to present with disseminated disease and are more
likely to have a negative TST when compared with immunocompe-
tent adults. [7–9] Children and people with HIV with a negative TST
in the setting of active TB have also been shown to have an increased
risk of TB-related death in small cohort studies. [10,11] We are not
aware of any studies that report an association between a negative
TST and death among other patient populations. However, we
hypothesized that other immunocompromised persons, and even
personswithoutovert immunedysfunction,whohaveanegativeTST
may also be at greater risk of death from TB disease. Thus, in addition
to its diagnostic utility for assessing infection with TB, the TST also
may have prognostic value in patients with TB. To further
characterize the relationship between TST and TB treatment
outcomes, we evaluated whether there is an association between
TST result and death among all persons with incident TB disease in
the United States over a 15 year period.
Methods
We analyzed all persons reported as new tuberculosis cases using
standardizedcasereport forms to theCenters forDiseaseControland
Prevention (CDC) National Tuberculosis Surveillance System from
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January 1, 1993 through December 31, 2008 who had a positive
culture result for MTBC at baseline, a documented TST result from
the time of diagnosis, and a documented outcome of either
completion of TB therapy or death from any cause after initiating
TB therapy and prior to completion of therapy. [12] We excluded
reports from California because HIV status has not been routinely
reported from that jurisdiction. [13] In the interest of comparing
groups with similar drug susceptibility patterns and treatment
histories we also limited the analysis to persons with (1) drug-
susceptible TB (no documented resistance to any of the standard first
line drugs [isoniazid, rifampin, pyrazinamide, and ethambutol]) with
no prior history of TB who were started on standard four-drug first
line therapy; (2) isoniazid monoresistant TB (documented resistance
to isoniazid but rifampin-susceptible); or (3) multidrug-resistant
(MDR) TB (resistance to at least rifampin and isoniazid). Based on
CDC guidelines for the classification of TST reactions, TST result
was divided into categories of 0–4 mm, 5–9 mm, 10–14 mm, and
$15 mm; a TST result of 0–4 mm was considered negative [14].
We compared the proportion of persons who died within each
category of TST result using the Pearson’s chi-squared test. We
also performed multivariate analysis using logistic regression to
determine the association between TST result and mortality.
Based on previous data and an a priori interest we adjusted the
model for age, sex, and HIV status. [4,15,16] We also adjusted for
origin of birth (US-born or foreign-born) since most foreign-born
persons in the US were vaccinated in their countries of origin with
Bacillus Calmette-Guerin (BCG) which can cause a positive TST
response. [17,18] Finally, we attempted to account for severity of
TB disease by adjusting the model for anatomic site of disease
including the presence or absence of cavitation on chest
radiograph for those with exclusively pulmonary disease (i.e.,
cavitary pulmonary, non-cavitary pulmonary, extrapulmonary
only, combined pulmonary and extrapulmonary, and miliary),
sputum smear acid fast bacilli (AFB) status at baseline, and the
drug susceptibility categories listed above.
Ethics Statement
Data were collected and analyzed for this project as part of
routine disease surveillance activities conducted by the US Centers
for Disease Control and Prevention (CDC) and does not constitute
research requiring review for the protection of human subjects.
Results
From 1993 through 2008, there were 284,866 cases of
tuberculosis reported in the United States of which 251,366 either
completed therapy or died. There were 8,516 persons who died
either prior to or at the time of diagnosis and an additional 20,020
persons who initiated therapy but did not complete treatment for
the following reasons: loss to follow-up (7,564), having moved
(8,906), adverse reactions (5), refusal to comply with therapy
(1,898), unknown reason (15,127). (There were 4,964 patients who
were missing data regarding completion of therapy.) Of the cases
that completed therapy or died, 197,919 cases had culture-
confirmed disease, 104,638 had a documented TST result, and
58,180 met criteria for inclusion in the analysis (Figure 1). People
with HIV infection, US-born persons, persons older than 65 years,
and those with smear-negative, extrapulmonary, or miliary disease
were less likely to have a TST result reported and therefore less
likely to be included in the analysis (Table 1).
Figure 1. Flow diagram of cases included in the analysis.
doi:10.1371/journal.pone.0078779.g001
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Among the 58,180 persons included in the analysis, 14% had a
TST of 0–4 mm, 2% had a TST of 5–9 mm, 23% had a TST of 10–
14 mm, and 61% had a TST$15 mm. Of 3,270 deaths, 1,388 (42%)
occurred in persons with a negative TST and increasing TST
indurationsizewasassociatedwithdecreasingoddsofdeath (Table2).
Persons with a TST$15 mm had 67% lower odds of death than
persons with a negative TST (adjusted odds ratio [aOR] 0.33, 95%
confidence interval [95% CI] 0.30–0.36). An increased odds of death
was found in persons older than 45 years, persons with HIV infection
or unknown HIV status, US-born persons, and those with
disseminated, AFB smear-positive, or drug-resistant disease. Of
note, inclusionofallpersonswithadocumentedTSTresult regardless
of culture result (e.g., including cases diagnosed clinically) did not
appreciably alter the results of the analysis (n = 145,108:5–9 mm
aOR 0.47, 95% CI 0.40–0.54; 10–14 mm aOR 0.36, 95% CI 0.34–
0.39; $15 mm aOR 0.28, 95% CI 0.26–0.30).
Conclusions
We observed that patients reported to the US surveillance
system with culture-confirmed active TB and a negative TST
result were significantly more likely to die after initiation of TB
treatment than patients with a positive TST result. This
relationship persisted even after adjustment for HIV status, site
of TB disease, sputum smear AFB status at baseline, drug
susceptibility at baseline, age, sex, and origin of birth.
Our results are consistent with several smaller studies of
children, persons with HIV, and immunocompetent adults where
a negative TST in the setting of active disease has been associated
with a two to three-fold increase in the risk of death. [10,11,19]
The risk of death associated with a negative TST at the time of
disease is also evident in a native Brazilian population with high
rates of anergy (46%), severe clinical manifestations, and high
mortality from TB disease [20].
ThebenefitofhavingapositiveTSTat thetimeofdiseasemayhave
parallels with the effects of BCG vaccination in early childhood. In
general, children who have been vaccinated show a transient positive
TST response and are less likely to develop disseminated forms of
disease, and are less likely to die if they do develop TB disease. [21,22]
Our results suggest that the host immune response in the setting of
active TB disease that is measured by a TST might be similar to the
immune response triggered by BCG vaccination in children and
potentially mitigates against death.




% of all reported cases





Total 284,866 56 226,686 (80) 58,180 (20)
Sex
Male 178,475 (63) 55 140,943 (62) 37,532 (65)
Female 106,339 (37) 57 85,694 (38) 20,645 (35)
Age
0–4 years 10,518 (4) 86 9,954 (4) 564 (1)
5–14 years 7,361 (3) 88 6,740 (3) 621 (1)
15–24 years 26,328 (9) 71 18,550 (8) 7,778 (13)
25–44 years 100,016 (35) 57 75,892 (34) 24,034 (41)
45–64 years 78,501 (28) 52 61,962 (27) 16,539 (28)
65+ years 61,988 (22) 43 53,360 (24) 8,628 (15)
HIV status
Positive 29,852 (10) 38 24,830 (11) 5,022 (9)
Negative 104,918 (37) 64 69,196 (30) 35,722 (61)
Unknown 150,096 (53) 54 132,660 (59) 17,436 (30)
Origin of birth
US-born 152,678 (54) 53 122,139 (54) 30,539 (53)
Foreign-born 130,783 (46) 59 103,238 (46) 27,545 (47)
Site of TB disease
Cavitary pulmonary 57,183 (21) 58 40,373 (19) 16,810 (30)
Non-cavitary pulmonary 141,474 (52) 59 113,751 (52) 27,723 (49)
Extrapulmonary only 53,217 (19) 52 45,486 (21) 7,731 (14)
Pulmonary/Extrapulmonary 16,878 (6) 50 13,436 (6) 3,442 (6)
Miliary 5,035 (2) 40 4,274 (2) 761 (1)
Smear status at baseline
Positive 103,984 (37) 52 75,260 (33) 28,724 (49)
Negative 114,317 (40) 62 93,169 (41) 21,148 (36)
Unknown/Not done 66,475 (23) 52 58,181 (26) 8,294 (14)
Deaths 24,472 (9) 31 21,202 (9) 3,270 (6)
doi:10.1371/journal.pone.0078779.t001
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Functional differences have been observed in the cytokine
profiles of TB patients who are TST-negative and TST-positive
including antigen-specific impairments in IL-2, IL-10, and IFN-c
production. [19,23–25] These impairments in cytokine production
and subsequent perturbations in the T-helper 1 and T-helper 2
balance of TST-negative patients may result in impaired ability to
control TB disease. Poor clinical outcomes of patients with
interferon-gamma receptor mutations and other forms of inherited
susceptibility to mycobacterial disease also underscore the
importance of cellular immune function, the basis of the TST
result, in the successful treatment of TB. [26] Together, these
observations indicate that patients with a negative TST may not
possess adequate immune function to control TB infection, even in
the setting of TB treatment. Future research is warranted to
examine how the TST result may serve as an indicator of
responsiveness to TB treatment.












Total 58,180 3,270 6
TST result
0–4 mm 8,368 (14) 1,388 (42) 17 Ref
5–9 mm 1,444 (2) 95 (3) 7 0.51 0.41, 0.64
10–14 mm 13,164 (23) 623 (19) 5 0.41 0.36, 0.45
$15 mm 35,204 (61) 1,164 (36) 3 0.33 0.30, 0.36
Sex
Male 37,532 (65) 2,314 (71) 6 Ref
Female 20,645 (35) 956 (29) 5 0.87 0.80, 0.95
Age
0–4 years 564 (1) 7 (0) 1 0.35 0.16, 0.74
5–14 years 621 (1) 3 (0) 0.5 0.25 0.08, 0.79
15–24 years 7,778 (13) 52 (2) 0.7 0.41 0.30, 0.55
25–44 years 24,034 (41) 757 (23) 3 Ref
45–64 years 16,539 (28) 993 (30) 6 2.37 2.13, 2.64
65+ years 8,628 (15) 1,454 (44) 17 8.26 7.36, 9.28
HIV status
Positive 5,022 (9) 796 (24) 16 5.66 5.03, 6.36
Negative 35,722 (61) 1,147 (35) 3 Ref
Unknown 17,436 (30) 1,327 (41) 8 1.64 1.50, 1.80
Origin of birth
US-born 30,539 (53) 2,429 (75) 8 Ref
Foreign-born 27,545 (47) 830 (25) 3 0.55 0.50, 0.60
Site of TB disease
Cavitary pulmonary 16,810 (30) 739 (24) 4 0.96 0.87, 1.06
Non-cavitary pulmonary 27,723 (49) 1,608 (52) 6 Ref
Extrapulmonary only 7,731 (14) 371 (12) 5 0.90 0.78, 1.04
Pulmonary/Extrapulmonary 3,442 (6) 280 (9) 8 1.45 1.25, 1.68
Miliary 761 (1) 124 (4) 16 2.36 1.89, 2.96
Sputum smear status at baseline
Positive 28,724 (49) 1,675 (51) 6 1.42 1.29, 1.56
Negative 21,148 (36) 907 (28) 4 Ref
Unknown/not done 8,294 (14) 687 (21) 8 1.85 1.64, 2.09
Drug susceptibility class
Drug-susceptible 52,781 (91) 2,887 (88) 5 Ref
Isoniazid monoresistant 4,498 (8) 236 (7) 5 1.23 1.06, 1.43
MDR TB 901 (2) 147 (5) 16 5.16 4.17, 6.38
*Pearson’s chi-square p-value ,.0001 for all categories.
**adjusted for TST, sex, age, HIV status, origin of birth, anatomic site of disease, cavitation on chest radiograph, sputum smear status at baseline, and drug susceptibility
class,
doi:10.1371/journal.pone.0078779.t002
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Tuberculin skin testing is considered an adjunctive test to
support the diagnosis of TB in the United States. [27] Our data
indicate that tuberculin skin testing is not consistently performed
as only 56% of patients with TB disease in the surveillance
database had a TST result reported. We found that persons with
HIV, persons older than 65 years, and persons with extrapulmo-
nary or miliary disease were less likely to have a TST result
reported. These groups are also more likely to have a negative
TST and so it is possible that the association between TST and
death is even stronger than what we found in our analysis. We
were not able to determine the effect of other immunocompromis-
ing conditions on TST and outcome because U.S. surveillance
data prior to 2009 do not include information on conditions, other
than HIV infection, such as nutritional status, diabetes mellitus,
chronic renal disease, or treatments such as TNF-a antagonists
that affect immune function and may impact TST results.
[1,4,9,28] Furthermore, data from California, which accounts
for approximately 20% of TB cases in the United States, were
excluded because HIV results were not routinely reported to
CDC. Recognizing these limitations of surveillance data it will be
necessary to conduct prospective research to verify the findings of
this retrospective observational surveillance data analysis.
We recommend increased utilization of the TST in clinical
research to systematically evaluate how the TST result may inform
clinical care of persons with TB. In addition to serving as a marker
of the risk of developing active disease among TB contacts, the
TST result appears to be a marker for risk of death in patients with
TB disease. However, further research is needed to determine
what host or pathogen factors contribute to this increased risk of
death observed among patients with a negative TST, and also to
determine whether the same associations with death are seen with
the newer interferon gamma release assays. Further study of the
factors associated with death among patients with a negative TST
may help identify strategies to improve survival.
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